Unstable major molecular response as a trigger for next generation sequencing‐based BCR::ABL1 mutation testing in chronic myeloid leukemia
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27232 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Adela Benesova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, Agentura Pro Zdravotnický Výzkum České Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy.
Abstract (Originalsprache)
To the Editor: In chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs), molecular response (MR) milestones have been identified that harbor prognostic significance. Major molecular response (MMR) — defined as 3-log reduction in BCR::ABL1 transcript levels from the standardized baseline on the International Scale (IS) — was the very first of such MR milestones to be recognized: It emerged at the time of the IRIS trial as a “ safe haven ” protecting from loss of response and progression. 1 According to the ELN recommendations, achievement of MMR after 12 months of TKI treatment defines an optimal response whereas failure to achieve MMR or loss of MMR represents a warning, requiring the therapeutic strategy to be carefully evaluated for continuation or change. 2 Emerging TKI-resistant point mutations in the kinase domain (KD) of BCR::ABL1 may underlie warning responses in a proportion of patients, tilting the balance toward treatment change.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- Department of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology "Lorenzo e Ariosto Seràgnoli", University of Bologna, Bologna, Italy.
- Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Jena University Hospital, Jena, Germany.
ORCID-Profile: Simona Soverini, Katerina Machova Polakova
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
- Agentura Pro Zdravotnický Výzkum České Republiky
- Ministerstvo Školství, Mládeže a Tělovýchovy
- Ministerstvo Školství, Mládež a Tělovýchovy
Zitieren
APA
Benesova, A., De Santis, S., Polivkova, V., Pecherkova, P., Krizkova, J., Suchankova, P., Monaldi, C., Klamova, H., Srbova, D., Zizkova, H., Hochhaus, A., Soverini, S., & Machova Polakova, K. (2024). Unstable major molecular response as a trigger for next generation sequencing‐based BCR::ABL1 mutation testing in chronic myeloid leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27232
Vancouver
Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, et al. Unstable major molecular response as a trigger for next generation sequencing‐based BCR::ABL1 mutation testing in chronic myeloid leukemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27232
BibTeX
@article{Benesova2024,
author = {Benesova, Adela and De Santis, Sara and Polivkova, Vaclava and Pecherkova, Pavla and Krizkova, Jitka and Suchankova, Pavla and Monaldi, Cecilia and Klamova, Hana and Srbova, Dana and Zizkova, Hana and Hochhaus, Andreas and Soverini, Simona and Machova Polakova, Katerina},
title = {Unstable major molecular response as a trigger for next generation sequencing‐based BCR::ABL1 mutation testing in chronic myeloid leukemia},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27232}
}
EUVIMED